|
1
|
Compare D, Rocco A and Nardone G: Risk
factors in gastric cancer. Eur Rev Med Pharmacol Sci. 14:302–308.
2010.PubMed/NCBI
|
|
2
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma L and Weinberg RA: Micromanagers of
malignancy: Role of microRNAs in regulating metastasis. Trends
Genet. 24:448–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zamore PD and Haley B: Ribo-gnome: The big
world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Valastyan S, Reinhardt F, Benaich N,
Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and
Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits
breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang CJ, Stratmann J, Zhou ZG and Sun XF:
Suppression of microRNA-31 increases sensitivity to 5-FU at an
early stage, and affects cell migration and invasion in HCT-116
colon cancer cells. BMC Cancer. 10:6162010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang WH, Gui JH, Wang CZ, Chang Q, Xu SP,
Cai CH, Li YN, Tian YP, Yan L and Wu B: The identification of
miR-375 as a potential biomarker in distal gastric adenocarcinoma.
Oncol Res. 20:139–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schaefer A, Jung M, Mollenkopf HJ, Wagner
I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung
K: Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
14
|
Creighton CJ, Fountain MD, Yu Z, Nagaraja
AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, et
al: Molecular profiling uncovers a p53-associated role for
microRNA-31 in inhibiting the proliferation of serous ovarian
carcinomas and other cancers. Cancer Res. 70:1906–1915. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B,
Gu J, Chen HY and Sun XF: Clinicopathological significance of
microRNA-31, −143 and −145 expression in colorectal cancer. Dis
Markers. 26:27–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Motoyama K, Inoue H, Takatsuno Y, Tanaka
F, Mimori K, Uetake H, Sugihara K and Mori M: Over- and
under-expressed microRNAs in human colorectal cancer. Int J Oncol.
34:1069–1075. 2009.PubMed/NCBI
|
|
17
|
Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY,
Wu KJ, Chiou SH, Lin SC and Chang KW: miR-31 ablates
expression of the HIF regulatory factor FIH to activate the HIF
pathway in head and neck carcinoma. Cancer Res. 70:1635–1644. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong QW, Lung RW, Law PT, Lai PB, Chan KY,
To KF and Wong N: MicroRNA-223 is commonly repressed in
hepatocellular carcinoma and potentiates expression of
Stathmin1. Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Sempere LF, Ouyang H, Memoli VA,
Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, et al:
MicroRNA-31 functions as an oncogenic microRNA in mouse and human
lung cancer cells by repressing specific tumor suppressors. J Clin
Invest. 120:1298–1309. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun Z, Li DM, Wang ZN, Huang BJ, Xu Y, Li
K and Xu HM: Prognostic significance of microscopic positive
margins for gastric cancer patients with potentially curative
resection. Ann Surg Oncol. 16:3028–3037. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang CG, Wang ZN, Sun Z, Liu FN, Yu M and
Xu HM: Clinicopathologic characteristics and prognosis of gastric
cancer invading the subserosa. J Surg Oncol. 102:737–741. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng L, Pu J, Qi T, Qi M, Li D, Xiang X,
Huang K and Tong Q: miRNA-145 targets v-ets erythroblastosis virus
E26 oncogene homolog 1 to suppress the invasion, metastasis, and
angiogenesis of gastric cancer cells. Mol Cancer Res. 11:182–193.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang S, He L, Zhao X, Miao Y, Gu Y, Guo
C, Xue Z, Dou W, Hu F, Wu K, et al: MicroRNA let-7f inhibits tumor
invasion and metastasis by targeting MYH9 in human gastric cancer.
PLoS One. 6:e184092011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the Robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paterson HF, Self AJ, Garrett MD, Just I,
Aktories K and Hall A: Microinjection of recombinant p21rho induces
rapid changes in cell morphology. J Cell Biol. 111:1001–1007. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takaishi K, Kikuchi A, Kuroda S, Kotani K,
Sasaki T and Takai Y: Involvement of rho p21 and its
inhibitory GDP/GTP exchange protein (rho GDI) in cell
motility. Mol Cell Biol. 13:72–79. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kishi K, Sasaki T, Kuroda S, Itoh T and
Takai Y: Regulation of cytoplasmic division of Xenopus embryo by
rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI). J
Cell Biol. 120:1187–1195. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jantsch-Plunger V, Gönczy P, Romano A,
Schnabel H, Hamill D, Schnabel R, Hyman AA and Glotzer M: CYK-4: A
Rho family gtpase activating protein (GAP) required for central
spindle formation and cytokinesis. J Cell Biol. 149:1391–1404.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirata K, Kikuchi A, Sasaki T, Kuroda S,
Kaibuchi K, Matsuura Y, Seki H, Saida K and Takai Y: Involvement of
rho p21 in the GTP-enhanced calcium ion sensitivity of
smooth muscle contraction. J Biol Chem. 267:8719–8722.
1992.PubMed/NCBI
|
|
30
|
Gong MC, Iizuka K, Nixon G, Browne JP,
Hall A, Eccleston JF, Sugai M, Kobayashi S, Somlyo AV and Somlyo
AP: Role of guanine nucleotide-binding proteins - ras-family or
trimeric proteins or both - in Ca2+ sensitization of
smooth muscle. Proc Natl Acad Sci USA. 93:1340–1345. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perona R, Esteve P, Jiménez B, Ballestero
RP, Cajal Ramóny S and Lacal JC: Tumorigenic activity of rho genes
from Aplysia californica. Oncogene. 8:1285–1292.
1993.PubMed/NCBI
|
|
32
|
Prendergast GC, Khosravi-Far R, Solski PA,
Kurzawa H, Lebowitz PF and Der CJ: Critical role of Rho in cell
transformation by oncogenic Ras. Oncogene. 10:2289–2296.
1995.PubMed/NCBI
|
